MedTrace Logo

Multimodal Assessment of Frailty in Acute Stroke Patients

NCT06031909 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-09-11

No results posted yet for this study

Summary

The goal of this study is to investigate the influence of frailty on clinical and stroke characteristics, treatment and outcomes in patients with acute stroke.

The main questions it aims to answer are:

1. How prevalent is frailty in patients with stroke?
2. Which impairments (e.g. undernutrion, impaired mobility, laboratory markers) contribute to frailty?
3. Is the outcome of frail patients worse than those without?
4. Are in-hospital complications more frequent in frail patients than those without?

Conditions

Interventions

DIAGNOSTIC_TEST

Multimodal frailty assessment

Different domains are assessed during hospital stay, these include: * Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI) * Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging * Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers * Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS) * Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle.

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Stefan Gerner, MD · Department of Neurology, University Hospital Giessen/Germany

  • Thorsten Doeppner, MD · Department of Neurology, University Hospital Giessen/Germany

  • Hagen Huttner, MD, PhD · Department of Neurology, University Hospital Giessen/Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031909 on ClinicalTrials.gov